Skip to main content
SpringerLink
Log in

Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Rituximab, a chimeric murine/human monoclonal anti-CD20 antibody, was licensed for the treatment of B-cell lymphoma and has also shown efficacy against autoimmune diseases such as immune thrombocytopenic purpura (ITP). It is relatively safe; however, about 1–20% of patients were reported to have developed rituximab-induced serum sickness, which is more common among patients with autoimmune conditions than among those with hematologic malignancies. Here we describe a pediatric patient with steroid-dependent chronic ITP who presented with arthralgia and fever ten days after the second infusion of rituximab (on day 10), and presented with malaise and maculopapular rash on day 21. Oral prednisolone was started and his symptoms resolved. He had an elevated level of human anti-chimeric antibody (HACA) on day 27; thereafter, the HACA level slowly decreased. To our knowledge, among pediatric patients who received rituximab for chronic ITP, this is the sixth documented case of serum sickness and the only one who manifested an elevated level of HACA. Rituximab is a beneficial treatment option against chronic ITP; however, the risk of serum sickness should be considered. Steroid, usually used for the treatment of serum sickness, may prevent the development of severe serum sickness when administered during and after rituximab treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Stevens W, Koene H, Zwaginga JJ, Vreugdenhil G. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Neth J Med. 2006;64:356–63.

    CAS  PubMed  Google Scholar 

  2. Tamminga RY, Bruin MC. Rituximab treatment for symptomatic chronic ITP. Pediatr Blood Cancer. 2006;47:714–6. doi:10.1002/pbc.20967.

    Article  PubMed  Google Scholar 

  3. Peñalver FJ, Jiménez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85:400–6. doi:10.1007/s00277-006-0123-3.

    Article  PubMed  Google Scholar 

  4. Panzer S. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review. Vox Sang. 2008;94:1–5.

    CAS  PubMed  Google Scholar 

  5. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol. 2000;27:99–103.

    CAS  PubMed  Google Scholar 

  6. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–7. doi:10.1182/blood.V98.4.952.

    Article  CAS  PubMed  Google Scholar 

  7. Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood. 2002;99:3872–3. doi:10.1182/blood-2002-02-0392.

    Article  CAS  PubMed  Google Scholar 

  8. Giagounidis AA, Anhuf J, Schneider P, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol. 2002;69:95–100. doi:10.1034/j.1600-0609.2002.02686.x.

    Article  CAS  PubMed  Google Scholar 

  9. Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005;78:275–80. doi:10.1002/ajh.20276.

    Article  CAS  PubMed  Google Scholar 

  10. Neunert CE, Bright BC, Buchanan GR. Severe chronic refractory immune thrombocytopenic purpura during childhood: a survey of physician management. Pediatr Blood Cancer. 2008; 51:513–6.

    Article  PubMed  Google Scholar 

  11. Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005;146:217–21. doi:10.1016/j.jpeds.2004.09.004.

    Article  CAS  PubMed  Google Scholar 

  12. Bennet CM, Rogers ZR, Kinnamon DD et al. Prospective phase I/II study of rituximab in children and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639–42. doi:10.1182/blood-2005-08-3518.

    Article  Google Scholar 

  13. Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol. 2007;34:430–3.

    PubMed  Google Scholar 

  14. Edwards JC, Szczepanski L, Szczepanski J, et al. Effect of B-cell targeted therapy with rituximab in patients with rhenmatoid arthritis. N Engl J Med. 2004;350:2572–81. doi:10.1056/NEJMoa032534.

    Article  CAS  PubMed  Google Scholar 

  15. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr. 2002;141:683–8. doi:10.1067/mpd.2002.128547.

    Article  PubMed  Google Scholar 

  16. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740–50. doi:10.1002/art.21260.

    Article  CAS  PubMed  Google Scholar 

  17. D’Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine–human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum. 2001;44:1717–8. doi:10.1002/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C.

    Article  PubMed  Google Scholar 

  18. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol. 2002;70:329. doi:10.1002/ajh.10127.

    Article  PubMed  Google Scholar 

  19. Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol. 2003;14:1792. doi:10.1093/annonc/mdg488.

    Article  CAS  PubMed  Google Scholar 

  20. Catuogno M, Rezai S, Priori R, Magrini L, Valesini G. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology. 2005;44:406. doi:10.1093/rheumatology/keh470.

    Article  CAS  PubMed  Google Scholar 

  21. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913–20. doi:10.1136/ard.2004.029694.

    Article  CAS  PubMed  Google Scholar 

  22. Portlock CS, O’Connor OA, Straus DJ, et al. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation? Leuk Lymphoma. 2006;47:1260–4. doi:10.1080/10428190600565354.

    Article  CAS  PubMed  Google Scholar 

  23. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis. 2007;66:351–7. doi:10.1136/ard.2006.057919.

    Article  CAS  PubMed  Google Scholar 

  24. Schutgens RE. Rituximab-induced serum sickness. Br J Haematol. 2006;135:147. doi:10.1111/j.1365-2141.2006.06214.x.

    Article  PubMed  Google Scholar 

  25. DeMonaco NA, Jacobs SA. Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan. Clin Nucl Med. 2007;32:933–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Saiseikai Yokohamashi Nanbu Hospital, 3-2-10 Kounanndai Kounan-ku, Yokohama, 234-8503, Japan

    Shoko Goto, Reo Tanoshima, Hiromi Kato, Hiroyuki Takahashi & Sumio Kai

  2. Department of Pediatrics, Yokohama City University, Yokohama, Japan

    Hiroaki Goto

  3. Department of Orthopedics, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan

    Osamu Sekiguchi

Authors
  1. Shoko Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroaki Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reo Tanoshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiromi Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroyuki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Osamu Sekiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sumio Kai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shoko Goto.

About this article

Cite this article

Goto, S., Goto, H., Tanoshima, R. et al. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol 89, 305–309 (2009). https://doi.org/10.1007/s12185-009-0269-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-009-0269-6

Keywords

Search

Navigation